Fulcrum Therapeutics, Inc. closed fiscal year 2025 with $366.3M in total assets, $17.3M in total liabilities and $349.0M in shareholder equity. Total assets rose 40.5% from the prior fiscal year. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Fulcrum Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
FULC Balance Sheet by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY25S-4 | FY24S-4 | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $366.3M+40.5% | $260.7M+1.2% | $257.7M+13.7% | $226.7M-3.5% | $235.0M+81.4% | $129.6M+17.3% | $110.4M+28.8% | $85.8M |
| Total Liabilities | $17.3M-2.3% | $17.7M-21.4% | $22.5M-18.9% | $27.7M+18.3% | $23.5M-31.8% | $34.4M+47.7% | $23.3M-84.4% | $149.4M |
| Total Equity | $349.0M+43.6% | $243.0M+3.3% | $235.2M+18.2% | $198.9M-6.0% | $211.5M+122.2% | $95.2M+9.2% | $87.2Mn/m | -$63.7M |
FULC Balance Sheet by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4 | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'24S-4 | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $310.8M+44.7% | $324.0M+41.6% | $346.8M+42.9% | $366.3M+40.5% | $214.9M-23.0% | $228.8M-22.2% | $242.6M+4.3% | $260.7M+1.2% | $279.0M0.0% | $294.3M-2.0% | $232.6M-27.6% | $257.7M+13.7% |
| Total Liabilities | $8.8M-46.7% | $13.3M-8.3% | $13.5M-4.9% | $17.3M-2.3% | $16.5M-24.1% | $14.5M-29.3% | $14.2M-25.4% | $17.7M-21.4% | $21.7M-7.3% | $20.5M-17.8% | $19.0M-23.6% | $22.5M-18.9% |
| Total Equity | $302.0M+52.3% | $310.7M+44.9% | $333.3M+45.9% | $349.0M+43.6% | $198.4M-22.9% | $214.4M-21.7% | $228.5M+7.0% | $243.0M+3.3% | $257.3M+0.7% | $273.8M-0.6% | $213.6M-27.9% | $235.2M+18.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Fulcrum Therapeutics, Inc. financials
Frequently Asked Questions
Fulcrum Therapeutics, Inc. closed fiscal year 2025 with $366.3M in total assets, $17.3M in total liabilities and $349.0M in shareholder equity.
Fulcrum Therapeutics, Inc. (FULC) total assets rose by 40.5% year over year, from $260.7M to $366.3M in fiscal year 2025.
Across the 8 fiscal years this page covers, Fulcrum Therapeutics, Inc. (FULC) total assets went from $85.8M in fiscal year 2018 to $366.3M in fiscal year 2025.
Fulcrum Therapeutics, Inc. (FULC) reported $310.8M in total assets in Q3 2026. This represents an increase of 44.7% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Fulcrum Therapeutics, Inc. (FULC) reported on that line in every period on record.